参考文献/References:
[1]Boussiotis VA.Molecular and biochemical aspects of the PD1 checkpoint pathway.N Engl J Med,2016,375(18):1767-1778.
[2]Pardoll D.Cancer and the immune system:basic concepts and targets for intervention.Semin Oncol,2015,42(4):523-538.
[3]Boussiotis VA,Chatterjee P,Li L.Biochemical signaling of PD1 on T cells and its functional implications.Cancer J,2014,20(4):265-271.
[4]Mezzadra R,Sun C,Jae LT,et al.Identification of CMTM6 and CMTM4 as PDL1 protein regulators.Nature,2017,549(7670):106-110.
[5]Burr ML,Sparbier CE,Chan YC,et al.CMTM6 maintains the expression of PDL1 and regulates antitumour immunity.Nature,2017,549(7670):101-105.
[6]Han W,Ding P,Xu M,et al.Identification of eight genes encoding chemokinelike factor superfamily members 18 (CKLFSF18) by in silico cloning and experimental validation.Genomics,2003,81(6):609-617.
[7]Su Y,Lin Y,Zhang L,et al.CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.Cancer Sci,2014,105(1):26-34.
[8]Gao D,Hu H,Wang Y,et al.CMTM8 inhibits the carcinogenesis and progression of bladder cancer.Oncol Rep,2015,34(6):2853-2863.
[9]SánchezPulido L,MartínBelmonte F,Valencia A,et al.MARVEL:a conserved domain involved in membrane apposition events.Trends Biochem Sci,2002,27(12):599-601.
[10]Jin MH,Nam AR,Park JE,et al.Therapeutic cotargeting of WEE1 and ATM downregulates PDL1 expression in fancreatic cancer.Cancer Res Treat,2019 Jun 25.［Epub ahead of print］.
[11]Guan X,Zhang C,Zhao J,et al.CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.EBioMedicine,2018,35:233-243.
[12]Koh YW,Han JH,Haam S,et al.Increased CMTM6 can predict the clinical response to PD1 inhibitors in nonsmall cell lung cancer patients.OncoImmunology,2019,8(10):e1629261.
[13]冯晓波,赵九洲,李武,等.PD1、PDL1、CMTM6在口腔鳞癌中的表达及意义.肿瘤学杂志,2019,25(6):577-580.
[14]Tu X,Qin B,Zhang Y,et al.PDL1 (B7H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy.Molecular Cell,2019,74(6):1215-1226.e1214.
[15]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2018,68(6):394-424.
[16]QuintanalVillalonga A,MolinaPinelo S.Epigenetics of lung cancer:a translational perspective.Cell Oncol (Dordr),2019 Aug 8.［Epub ahead of print］.
[17]丁雨,蒋敬庭.CMTM6在肺腺癌组织中的表达及其临床意义.中国肿瘤生物治疗杂志,2019,26(5):544-549.
[18]Yafune A,Kawai M,Itahashi M,et al.Global DNA methylation screening of liver in piperonyl butoxidetreated mice in a twostage hepatocarcinogenesis model.Toxicol Lett,2013,222(3):295-302.
[19]Zhu X,Qi G,Li C,et al.Expression and clinical significance of CMTM6 in hepatocellular carcinoma.DNA Cell Biol,2019,38(2):193-197.
[20]Bei C,Tan C,Zhu X,et al.Association between polymorphisms in CMTM family genes and hepatocellular carcinoma in guangxi of China.DNA and Cell Biology,2018,37(8):691-696.
[21]Mamessier E,Birnbaum DJ,Finetti P,et al.CMTM6 stabilizes PDL1 expression and refines its prognostic value in tumors.Ann Transl Med,2018,6(3):54.
[22]Birnbaum DJ,Finetti P,Lopresti A,et al.Prognostic value of PDL1 expression in pancreatic cancer.Oncotarget,2016,7(44):71198-71210.
[23]Xue S,Hu M,Li P,et al.Relationship between expression of PDL1 and tumor angiogenesis,proliferation,and invasion in glioma.Oncotarget,2017,8(30):49702-49712.
[24]Delic S,Thuy A,Schulze M,et al.Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets.Genes Chromosomes Cancer,2015,54(7):433-443.
[25]Zhao W,Zhao F,Yang K,et al.An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade.J Cell Biochem,2019,120(8):13330-13341.